CEP 2563

Drug Profile

CEP 2563

Alternative Names: CEP-2563; KT-8391

Latest Information Update: 26 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Class Antineoplastics
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 28 Jun 2002 No development reported - Phase-I for Solid tumours in USA (IV-infusion)
  • 31 Dec 2001 Schwarz Pharma has terminated its licence for CEP 2563
  • 13 Jan 2000 Schwarz Pharma has licensed rights to CEP 2563 in markets other than the US, Asia and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top